BPC-157 for Tendon Repair: What Research Reports

What is BPC-157 and why is it studied for tendons?

BPC-157 is a lab-made 15 amino acid peptide that animal research links to soft-tissue and tendon healing, mainly through new blood vessel growth.

The name stands for "Body Protection Compound 157." It is a stable synthetic pentadecapeptide (a peptide of 15 amino acids) first derived from a protein found in gastric juice (Sikiric et al., Gut and Liver 2019, PMID 31158953). It is not a hormone, not a steroid, and not an approved drug. Tendons are a natural target for repair research because they have a poor blood supply and heal slowly, so a compound reported to grow new vessels is an obvious thing to test on them. That is the appeal, but it is worth being clear from the first line: the tendon evidence for BPC-157 is built almost entirely on rats and cell cultures, and results in animals may or may not carry over to people.

For the full compound overview beyond tendons, see /bpc-157. For how peptides work in general, see /what-are-peptides.

How might BPC-157 help tendons heal?

Research describes three connected actions: growing new blood vessels, helping repair cells survive and move, and raising how strongly tendon cells respond to growth hormone.

The first and best-documented action is angiogenesis, the growth of new blood vessels. The Sikiric review (Gut and Liver 2019, PMID 31158953) ties BPC-157's healing effects across tissue types to activation of the VEGFR2 receptor (vascular endothelial growth factor receptor 2) and the nitric oxide (Akt-eNOS) pathway, which together drive new vessel formation. For a tendon, which starts with little blood supply, more vessels means more oxygen and nutrients reaching the repair site.

The second action is at the cell level. Chang et al. (J Appl Physiol 2011, PMID 21030672) worked with tendon fibroblasts (the cells that build tendon tissue) taken from rat Achilles tendon. BPC-157 sped up the outgrowth of cells from tendon explants, increased cell survival under oxidative (hydrogen peroxide) stress, and increased cell migration in a dose-dependent way. It did this without directly speeding cell division. The authors linked the migration effect to the FAK-paxillin pathway, which controls how cells attach to and crawl across a surface during repair.

The third action is a growth-hormone connection, and it is the piece most specific to tendons. Chang et al. (Molecules 2014;19(11):19066-77, PMID 25415472), a separate cell study using rat Achilles tendon fibroblasts, reported that BPC-157 increased growth hormone receptor expression up to about sevenfold over three days. When growth hormone was then added, the pretreated cells showed more proliferation and more JAK2 signaling (JAK2 is an enzyme that carries the growth-hormone signal inside the cell). In plain terms, the study suggests BPC-157 may make tendon cells more sensitive to a repair signal the body already uses. Both Chang studies were done in cultured cells, and the authors of the 2014 paper noted that cultured cells cannot fully mimic real tendon healing, since other cells like immune cells and stem cells also take part in living tissue.

What does animal research report on tendon-to-bone healing?

The strongest tendon result is that BPC-157 improved Achilles tendon-to-bone healing in rats across functional, mechanical, and microscopic measures, and blunted the harm a corticosteroid caused.

The lead study is Krivic et al. (J Orthop Res 2006, doi:10.1002/jor.20096, PMID 16583442). Researchers cut the Achilles tendon away from the heel bone in rats, then gave BPC-157 once a day. Compared with saline, the treated animals healed better in three ways at once. Functionally, their Achilles functional index (a walking-based score) was substantially higher. Mechanically, the healing tendon had greater load to failure, stiffness, and elasticity, meaning it was stronger. Microscopically, the tissue showed better-organized collagen fibers, more new blood vessels, and more type I collagen (the main structural collagen of tendon). In the same study, a corticosteroid consistently made healing worse, and BPC-157 substantially reduced that corticosteroid-driven damage.

A follow-up by the same group, Krivic et al. (Inflamm Res 2008;57(5):205-10, doi:10.1007/s00011-007-7056-8, PMID 18594781), looked at the earliest phase of Achilles tendon-to-bone recovery in rats and again reported that BPC-157 improved early functional recovery, while the corticosteroid methylprednisolone impaired it.

The honest limitation, stated plainly: this is rat and cell data. There is no large, controlled human trial showing BPC-157 heals human tendons. A 2025 narrative review (McGuire et al., Curr Rev Musculoskelet Med 2025, PMCID PMC12446177) found only about three published human studies of BPC-157 of any kind and concluded that, until well-designed human trials exist, it should not be recommended for clinical use in musculoskeletal medicine. Read the animal tendon findings as hypotheses about people, not proof.

What dosing does BPC-157 tendon research report?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Almost all published BPC-157 tendon dosing comes from rat studies, where the dose is given per animal or per kilogram of body weight, usually as an injection into the abdominal cavity (intraperitoneal). Animal doses do not translate directly to a human dose, and there is no established, trial-validated human dose for tendon repair. The table shows what specific tendon studies used, with the source for each.

A note on unit math, shown generically as a reference and not as an instruction: a research dose in micrograms only maps to an insulin-syringe "unit" reading after a peptide is dissolved in a known volume of liquid. As a generic example, if 5 mg of any peptide is dissolved in 2 mL of liquid, that is 2500 mcg per mL, and a U-100 insulin syringe reads 100 units per mL, so 1 mcg corresponds to 0.04 units on that scale. This is arithmetic for reading a label, not guidance to dose.

What are realistic expectations for BPC-157 for tendon repair?

Realistic expectation: the tendon evidence is promising in animals and thin in humans, so no result is established for people, and no timeline can be promised.

It helps to separate what the research actually measured from what gets claimed online. What research measured: faster, stronger, better-organized tendon-to-bone healing in rats (Krivic et al., 2006, PMID 16583442), and more tendon-cell outgrowth, survival, and migration in culture (Chang et al., 2011, PMID 21030672). What the research did not do: run a controlled trial in people with a tendon injury and measure recovery. Because of that gap, claims like "heals your tendon in X weeks" are not supported by the evidence, no matter how confidently they are stated. The 2025 review is blunt about this, calling human data extremely limited and advising against clinical use until trials exist (McGuire et al., 2025, PMCID PMC12446177). Treat BPC-157 as an investigational research compound with encouraging animal tendon data, not a proven tendon therapy.

What are the side effects and cautions?

Animal studies report a wide safety margin, but human safety data are very limited, and BPC-157 is not an approved medicine.

In rodent work, BPC-157 has generally been reported as well tolerated across a broad dose range, and the Sikiric review (Gut and Liver 2019, PMID 31158953) notes no adverse effects in the very limited human exposure to date. That is not the same as an established human safety profile, because it rests on animal data plus tiny human exposure. One mechanism-based caution matters here: BPC-157's core tendon-repair action is pro-angiogenic (it promotes new blood vessel growth, per the Sikiric review). Since tumors also depend on new blood vessels, researchers raise anything pro-angiogenic as a theoretical concern in the setting of cancer. This is a mechanism-based caution, not a documented human harm.

Two status facts round out the picture. The U.S. Food and Drug Administration has not approved BPC-157 for any use, and its regulatory status under compounding rules has been in flux: in 2023 the FDA placed BPC-157 in Category 2 of its Section 503A bulk drug substances review, the group flagged for significant safety risks or insufficient data, and in April 2026 it removed BPC-157 from that Category 2 list pending a fresh Pharmacy Compounding Advisory Committee review, which does not amount to approval (FDA, Bulk Drug Substances Used in Compounding Under Section 503A). And because any injectable research compound carries injection-site risks and purity concerns, reviewing a certificate of analysis is worth doing (see /coa). None of this is a safety guarantee, and groups where any investigational compound warrants extra caution, such as during pregnancy or breastfeeding, are exactly where the missing human data matters most.

How does BPC-157 compare with other tendon-repair peptides?

BPC-157 is most often compared with TB-500 (thymosin beta-4), another repair-focused peptide studied for overlapping goals through a different mechanism.

Both are studied mostly in animals for soft-tissue and wound repair. BPC-157's best-documented actions are VEGFR2-driven angiogenesis plus the FAK-paxillin and growth-hormone-receptor effects above, while TB-500 is a fragment of thymosin beta-4 studied for actin binding, cell migration, and angiogenesis. For a side-by-side breakdown of mechanism, evidence tier, and research-reported use, see /bpc157-vs-tb500. To compare across the wider set of repair compounds, see /peptides-for-recovery. For the compound's full profile beyond tendons, see /bpc-157.